Submissions from 2026
Are All Protective Styles Equal? Assessing Quality of Public Information on Risks for Afro-Textured Hair, Olamide Adebayo, Aliya Rogers, Kevin Truong-Balderas, Bianca E. Ituarte, Kayla Clark, and Erin X. Wei
Seborrheic Dermatitis Associated with an Increased Risk of Scarring Alopecia:A Multi-Center Retrospective Cohort Analysis, Nabeel Ahmad, Anika Felix, and Claire Hollins
Characterization of the Ihs4 Response to Lutikizumab Treatment in Biologic-Naive Patients with Moderate-to-Severe Hidradenitis Suppurativa (Hs), Raed Alhusayen, Christos C. Zouboulis, Hermenio Lima, Antonio Martorell, Brian Kirby, Iltefat H. Hamzavi, Konrad T. Sawicki, Amy Gamelli, Ruoyu He, Mona Akbari, and Alexa B. Kimball
Exposure–Response Modeling Predicted Long-Lasting Responses with Lebrikizumab Every 8 Week Maintenance Dosing for Moderate-to-Severe Atopic Dermatitis and Aligned with Observed Clinical Trial Data, April Armstrong, Andrew Blauvelt, Alan Irvine, Peter Lio, Linda Stein Gold, Gaia Gallo, Yuxin Ding, Hany Elmaraghy, Brian Moser, and Emma Guttman-Yassky
Sustained Health-Related Quality of Life and Work Productivity Improvements with Delgocitinib 20 Mg/G Cream in Chronic Hand Eczema-Results from the Phase 3 Open-Label Extension Delta 3 Trial, April Armstrong, Linda Stein Gold, Andrea Bauer, James Greig, Jenny M. Norlin, Henrik Thoning, and Tove Agner
Improvement in Atopic Dermatitis Signs and Symptoms With Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.15% or 0.05%: Results From the 52-Week Phase 3 INTEGUMENT-OLE Trial in Patients Aged ≥2 Years, Mark Boguniewicz, Chih Ho Hong, Lawrence Eichenfield, Alexandra Golant, Adelaide Hebert, Amy Paller, April Armstrong, Linda F. Stein Gold, David Krupa, Patrick Burnett, Diane Hanna, and Brett Stephenson
Efficacy of Sarecycline in the Treatment of Moderate-to-Severe Facial Acne Vulgaris (Av): Combined Results from Three Phase 3 Studies, James Del Rosso, Linda Stein Gold, Jianzhong Zhang, He Li, Valerie Callender, Glenn Dale, Lawrence Green, Jonathan Weiss, Ayoub Bentohami, Judit C. Robles, Paul Tomondy, and Jerry Tan
Long-Term Efficacy and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% (Cab) Gel for Acne in Participants with Fitzpatrick Skin Phototypes Iv-Vi: Pooled Results from Two 6-Month Studies, Zoe D. Draelos, Hilary Baldwin, Julie C. Harper, Mahmoud Ghannoum, Linda Stein Gold, Emil A. Tanghetti, and Leon H. Kircik
Performance of Gene Expression Profiling Versus Nomograms in Predicting Sentinel Lymph Node Positivity and Melanoma Recurrence, a Single Institution Retrospective Cohort Study, Rita El Jbeily, Raymond Zhao, Albert Young, Shakira Meltan, Aaron Tisack, Ben J. Friedman, and Natalie H. Matthews
Closing the Diagnostic Divide: Defining Global Access to Dermatopathology - a Skinobservatory Study, Esther Freeman, J. M. Yardman-Frank, P. Shamaei Zadeh, Henry W. Lim, N. Dlova, C. Fuller, C. E. M Griffiths, D. Kerob, and G. deLambert
Assessing Cancer Risk from Hair Dye Exposure, Rachel Greene, Jalal Maghfour, Cristina Nguyen, Gabby Baker, and Natasha Mesinkovska
Efficacy and Safety of Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Asian Participants with Moderate to Severe Acne, George Han, Andrew F. Alexis, Neal Bhatia, Valerie D. Callender, Hilary Baldwin, Eric Guenin, and Linda Stein Gold
No Association Found between Noontime Shade Coverage and Poverty Rates of Socioeconomically Diverse Zip Codes within Metro Detroit, Bianca Ituarte and Holly Kerr
A Global Assessment of Skin Health as a Public Health Priority: International Results from the Skinobservatory Study, Tebyan Khalfalla, Natalie Asemi, Joseph M. Yardman-Frank, Henry Lim, Ncoza Dlova, Claire Fuller, Chris Griffiths, Delphine Kerob, Guénolée de Lambert, and Esther Freeman
Tralokinumab Is Effective And Well-Tolerated In Adults With Atopic Dermatitis With Moderate-To-Severe Hand Involvement Who Are Candidates For Systemic Therapy: Week 16 Results From The Phase 3B ADHAND Trial, Andrea Krüger-Szabo, Benjamin Ehst, Richard Warren, Hong Chih-Ho, Juan F. Silvestre, Dong Hun Lee, Galina Balakirski, Andrei Metelitsa, Niels Højsager Bennike, Teodora Festini, Farzaneh Safavimanesh, and Linda F. Stein Gold
The Fourth-Generation Retinoid: Rational Molecular Design of Trifarotene, Selectivity, Efficacy, and Clinical Outcomes, Monica K. Li, Hilary Baldwin, Lawrence F. Eichenfield, Julie C. Harper, Firas G. Hougeir, Camille Howard Verovic, Naiem T. Issa, Jonette E. Keri, Neera R. Nathan, Linda Stein Gold, and Leon Kircik
Patients with Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nmsc), Lena Ly, Christopher Bunick, Linda Stein Gold, Ruth Ann Vleugels, Raj Chovatiya, David Cotter, Matthew Zirwas, Paula Luna, Chia-Yu Chu, Ayman Grada, Deanne Dilley, Meerat Oza, Emma Yue, Alena Pechonkina, Lani Wegrzyn, Gweneth Levy, and Jonathan Silverberg
Consensus Study on the Best Practices of Laser Hair Reduction for Hidradenitis Suppurativa, Teja Mallela, Akhil Wadhera, Iltefat Hamzavi, Colleen Cotton, Steven Daveluy, Mikael Horissian, Jessica St. John, Barry Resnik, and Christopher Sayed
Skin Microbiome Shifts in Basal Cell Carcinoma:A Pilot Whole-Genome Sequencing Study, Mavra Masood, David Ozog, Tengfei Ma, Marissa Ceresnie, Aunna Pourang, Christine Johnson, Xinyue Qiu, Albert Levin, and Jesse Veenstra
Characterizing Global Integration of Artificial Intelligence, Telehealth, and Electronic Medical Records in Dermatology: International Survey Results from the Ilds Skinobservatory Study, Georgiana McTigue, J. Michael Yardman-Frank, Jennifer Kilmer, Henry W. Lim, Delphine Kerob, L. Claire Fuller, Christopher E. M Griffiths, Ncoza C. Dlova, Guénolée de Lambert, and Esther Freeman
Clinical Demonstration of Pigmentation Response in Individuals with Fitzpatrick Skin Type V Following Irradiation with Novel Light Source at the Ultraviolet(Uv) / Visible Boundary Region, Selina Moses, Karen Meyer, Susan Daly, Joshua D. Williams, Indermeet Kohli, Tasneem Mohammad, and Henry Lim
Pigmentation and Oxidative Biomarker Modulation across All Skin Types (Fst I-Vi) Following Exposure to Boundary Region Wavelengths (Longest Ultraviolet a Plus High Energy Visible Light): A Controlled Clinical Study, Selina Moses, Thomas Shyr, Karen Meyer, Susan Daly, Joshua D. Williams, Indermeet Kohli, Tasneem Mohammad, and Henry Lim
More Than Just Multiple Melanomas: Insights from a Monoallelic Pot1 Mutation, Andrina Paul, Mardeen S. Karim, and Laurie Kohen
Characterizing Inpatient Hospitalizations for Hidradenitis Suppurativa and Assessing the Impact of Outpatient Dermatology Care on Hospitalizations, Akash Rau, Jasira Ziglar, Redina Bardhi, Jalal Maghfour, Vivian Liu, Brittani Jones, Nirajan Budhathoki, Richard Huggins, and Iltefat Hamzavi
Efficacy of Oral Dfd-29, a Low-Dose Minocycline Formulation, by Baseline Rosacea Severity in Two Phase 3 Trials, Srinivas Sidgiddi, Linda Stein Gold, Richard Gallo, Sunil Dhawan, Shraddha Bayar, and Srinivas Sidgiddi
Efficacy and Safety of Tapinarof Cream 1% Once Daily Monotherapy in Adults and Children with Atopic Dermatitis: Pooled Results from Adoring 1 and 2, Jonathan I. Silverberg, Lawrence F. Eichenfield, Linda Stein Gold, Juan C. Arjona Ferreira, and Robert Bissonnette
Continuous Response with Nemolizumab - Efficacy and Safety up to 104 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis with Partial and Non-Response in Skin at 16 Weeks: Post Hoc Analyses from the Arcadia Lte Trial, Jonathan I. Silverberg, Linda Stein-Gold, Diamant Thaçi, Andrew E. Pink, Franz J. Legat, April W. Armstrong, Soo Yeon Cheong, Liliana Ulianov, Anna Ryzhkova, and Christophe Piketty
Patients maintain stable response with no or minimal fluctuations during 3 years of continuous treatment with lebrikizumab during long-term extension trial, Jonathan Silverberg, Linda F. Stein Gold, Peter Lio, James del Rosso, Andreas Wollenberg, Jose-Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Helena Agell, Sebastian Diemert, and Christian Vestergaard
Long-Term Safety Analysis of Ruxolitinib Cream in Pediatric Patients With Atopic Dermatitis: An Integrated Analysis of 8 Clinical Trials, Dareen Siri, Lara W. Lee, Linda F. Stein Gold, April Armstrong, Kanwaljit Brar, Kristen Holland, Julie Shepard, Alim Devani, Howard Kallender, Vimal Patel, Haobo Ren, and Lawrence Eichenfield
The VPS72-H2A.Z-Axis Is an Underappreciated Oncogenic Vulnerability in Lung Adenocarcinoma, Xzaviar K. Solone, Selim Reza, Kalpana Subedi, Nirmal Parajuli, Li Zhou, and Qing-Sheng Mi
Treatment of Plaque Psoriasis Involving High-Impact Sites with Icotrokinra, a Targeted Oral Peptide: Pooled Analyses of 4 Phase 3 Placebo-Controlled Trials, Jennifer Soung, April W. Armstrong, Ronald B. Vender, Josep Riera-Monroig, Michael Sebastian, Ofelia Reyes-Servin, Bassey E. Edem, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, and Linda Stein Gold
Adolescents with Psoriasis in the United States: Current Treatment Landscape and Unmet Needs, Jennifer Soung, Linda Stein Gold, Nina Trenkler, Melina Taylor, Laurie Conklin, Jensen Lewis, Timothy Fitzgerald, Wesley Peters, Ya-Wen Yang, Guo Li, and Mona Shahriari
Durability of Response with Icotrokinra, a Targeted Oral Peptide, in Adults with Moderate-to-Severe Plaque Psoriasis: One-Year Results from the Phase 3, Placebo- and Active Comparator-Controlled Iconic-Advance 1 & Iconic-Advance 2 Trials, Linda Stein Gold, April W. Armstrong, Jennifer Soung, Ronald B. Vender, Álvaro González Cantero, Matthias Hoffmann, Ofelia Reyes-Servin, Bassey E. Edem, Kellen Cresswell, Ya-Wen Yang, and Robert Bissonnette
Consistency of Skin Clearance with the Targeted Oral Peptide Icotrokinra:Results from a Large Pooled Cohort of Phase 3 Study Participants with Moderate-to-Severe Plaque Psoriasis, Linda Stein Gold, April W. Armstrong, Jennifer Soung, Ronald B. Vender, Andrew E. Pink, Joseph Cafone, Bassey E. Edem, Ofelia Reyes-Servin, Shu Li, Ya-Wen Yang, and Mark G. Lebwohl
From Tretinoin to Trifarotene: Fifty Years of Innovation in Acne and Skin Health, Linda Stein Gold, Hilary Baldwin, James Q. Del Rosso, Seemal Desai, Julie C. Harper, Firas G. Hougeir, Camille H. Verovic, Leon Kircik, Monica K. Li, Neera R. Nathan, and Naiem T. Issa
Identifying Systemic-Ready Phenotype(S) to Estimate Systemic Treatment Needs with Predictive Analytics and Ehr Data among Us Topical-Initiating Psoriasis Patients, Linda Stein Gold, Michael Cameron, Rita De Cassia Castro, Cynthia Deignan, Kuan-Yu Chen, Kate Orroth, Kathy Tran, and April Armstrong
Efficacy of APG777 in Patients with Atopic Dermatitis and Evidence of Type 2 Inflammatory Comorbidities: Results from the Phase 2 APEX Study, Linda F. Stein Gold, Jonathan Silverberg, Andrew Blauvelt, Melinda Gooderham, Kenji Kabashima, Catherine Maari, Susanna Wen, Olivia Choi, Christine Wang, Li Xie, Joshua Cirulli, Kristine Nograles, Amol Kamboj, and Emma Guttman-Yassky
Efficacy of Apremilast in Patients with Mild to Moderate Psoriasis Involving the Scalp and Nails: A Post Hoc Analysis of the Phase 3 Advance Study, Linda Stein Gold, Melinda Gooderham, Eingun J. Song, David Pariser, Ulrich Mrowietz, Jennifer Soung, Mark Lebwohl, Mindy Chen, Jimena Vázquez, and Kim Papp
Spectrem: Guselkumab Skin Clearance and Patient-Reported Outcome Results across Skin and Joint Symptoms through Week 48 in Low Body Surface Area, Moderate Plaque Psoriasis with at Least One Moderate High-Impact Site Involved, Linda Stein Gold, Kim A. Papp, Richard G. Langley, Bruce Strober, April W. Armstrong, Robert Bissonnette, Alice B. Gottlieb, James G. Krueger, Joseph F. Merola, Theodore Alkousakis, and Mark G. Lebwohl
Efficacy of Apremilast in Patients with Moderate Psoriasis, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials, Bruce Strober, Mark Lebwohl, Peter van de Kerkhof, Linda Stein Gold, Joseph F. Merola, Yukari Okubo, Paolo Gisondi, Zhenwei Zhou, Siddharth Chaudhari, Cynthia Deginan, and Ulrich Mrowietz
Disparities in Racial Representation in Cosmetic Dermatology Clinical Trials, Calla Sullivan, Bianca Ituarte, Olamide Adebayo, Christopher Reagen, and Erin Wei
Clinical Effectiveness of Complementary and Alternate Therapies for Androgenetic Alopecia, Derya Turk, Rajaa Shoukfeh, and Geoffrey Potts
Dermatologic and Neuroimaging Features of Metastatic Melanoma and Neurocutaneous Syndromes, Derya Turk, Rajaa Shoukfeh, and Geoffrey Potts
Robust Icotrokinra Systemic and Skin Pharmacodynamic Effects Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis: Results from Phase 3, Iconic-Advance-1 Study, Richard B. Warren, Antonius P. J Van den Heuvel, Hurley Li, Elizabeth Chen, Julianty Angsana, Marta E. Polak, Nanna Yum, Cynthia DeKlotz, Nina Sabins, Linda Stein Gold, and Alvaro Gonzalez-Cantero
Exploring Skin Cancer Education Preferences among Solid Organ Transplant Recipients: A Survey Study, Marissa Yaldo, Rohini Prashar, and Holly Kerr
Submissions from 2025
62783 Beyond 7 years: Investigating Diagnostic Delay of Hidradenitis Suppurativa at an Urban Tertiary Care Dermatology Clinic, Deena Abdel-Gadir, Mavra Masood, Mohsen Mokhtari, Jaina Gaudette, Kameryn Abraskin, Jasira Ziglar, Iltefat Hamzavi, and Richard Huggins
64482 Optimization of Acquisition Techniques and Image Analysis in Optical Polarization Imaging for Basal Cell Carcinoma Margin Detection Prior to Mohs Surgery, Kamryn Abraskin, Jaina Gaudette, Mohsen Mokhtari, Brittani Jones, Monica Rosales Santillan, John Wuennenberg, Tyler Lorizzo, Anna Yaroslavsky, David Ozog, and Indermeet Kohli
Targeting B-cells in Hidradenitis Suppurativa: A Systematic Review of Bruton's Tyrosine Kinase Inhibition as a Target, Nabila Ahmed, Hafsa Hassan, Rebecca Quinonez, and Iltefat Hamzavi
A Persistent Scalp Plaque Resistant to Conventional Therapies, Aryan Arora, Caneisaya Matthews, and Karan Pandher
Occupational Allergic Contact Dermatitis in Manicurists: A Systematic Review, Nicholas Belair and Holly A. Kerr
0305 Topical and oral phosphodiesterase-4 inhibitors for refractory seborrheic dermatitis: A systematic review, Zane M. Berry, Meghan R. Mansour, and Joseph W. Fakhoury
0061 Interstitial granulomatous dermatitis: A case highlighting possible associations with myeloma and TNF-α inhibitor therapy, Zane M. Berry, Karan Pandher, Mustafa Jafry, and Marsha Chaffins
Interstitial granulomatous dermatitis: A case highlighting possible associations with myeloma and TNF-α inhibitor therapy, Zane M. Berry, Karan Pandher, Mustafa Jafry, and Marsha Chaffins
Skin clearance, treatment response off-therapy, and safety of tapinarof cream 1% once daily: results from ADORING 3, a 48-week Phase 3 trial in adults and children down to 2 years of age with atopic dermatitis, Robert Bissonnette, Linda F. Stein Gold, Leon Kircik, Eric Simpson, Lawrence F. Eichenfield, John Browning, Adelaide A. Hebert, Andrew F. Alexis, Weily Soong, Stephen C. Piscitelli, Anna M. Tallman, David S. Rubenstein, Philip M. Brown, and Jonathan I. Silverberg
62846 Efficacy of deucravacitinib in psoriasis by baseline total body surface area: post hoc analysis of the randomized, double-blind, placebo-controlled, phase 3b/4 PSORIATYK Scalp trial, Andrew Blauvelt, Matthias Hoffman, Linda F. Stein Gold, Jerry Bagel, Mark Lebwohl, Andrew Napoli, Chun-Yen Cheng, Rachel Dyme, Eugene Balagula, and Christopher E. M Griffiths
64608 Individual Clinical Response Trajectories to Lebrikizumab in Atopic Dermatitis: A Cluster Analysis, Andrew Blauvelt, Bruce Strober, Gaia Gallo, Yuxin Ding, Yun-Fei Chen, Martin Dossenbach, Lidia R. Calleja, Linda F. Stein Gold, and Jonathan Silverberg
64584 Skin of Color Society (SOCS) Project to Develop Inclusive Skin Assessment Tools, Valerie Callender, Andrew Alexis, Seemal Desai, Tarannum Jaleel, Henry W. Lim, Rashmi Sarkar, Susan Taylor, Jadesola Akanji, Hiba Mohammed, and Valerie Harvey
Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in hispanic participants with moderate-to-severe acne, Valerie D. Callender, Hilary Baldwin, Linda F. Stein Gold, Fran E. Cook-Bolden, and Andrew F. Alexis
Assessing genotypic, phenotypic, and polygenic risk associations of autoimmune comorbidities in FinnGen Finnish patients with vitiligo, Simon Chen, Mor Pavlovsky, Mary Pat Reeve, Thierry Passeron, Iltefat Hamzavi, Pranab Ghosh, Victoria Basey, and Roni Adiri
Assessing genotypic, phenotypic, and polygenic risk associations of autoimmune comorbidities in FinnGen patients with vitiligo, S. Chen, M. Pavlovsky, M. P. Reeve, T. Passeron, Iltefat Hamzavi, P. Ghosh, V. Basey, and R. Adiri
60502 Design and Rationale of ARMADA-AD Disease Registry: An International, Prospective, Observational Registry to Characterize Unmet Needs and Evaluate Real-World Effectiveness and Safety of Systemic Therapies in Adults and Adolescents with Atopic Dermatitis, Raj Chovatiya, Bob Geng, Thomas Bieber, Linda F. Stein Gold, Diamant Thaçi, Moataz Daoud, Kassim Rahawi, and Gopinath Nageshwaran
64222 Allergen Content in Best-Selling Sunscreens: A Comparison of Key Product Features, Christopher Chung, Emily Levin, Katia Hermes, Judy Hamad, Henry W. Lim, and Natalie Matthews
0680 Proteomics identifies blood biomarkers associated with disease severity and genetic ancestry in hidradenitis suppurativa, Peter Dimitrion, Rachel Krevh, Jesse Veenstra, Iltefat Hamzavi, Indra Adrianto, Li Zhou, and Qing-Sheng Mi
0680 Proteomics identifies blood biomarkers associated with disease severity and genetic ancestry in hidradenitis suppurativa, Peter Dimitrion, Rachel Krevh, Jesse Veenstra, Iltefat Hamzavi, Indra Adrianto, Li Zhou, and Qing-Sheng Mi
TRALOKINUMAB IS EFFECTIVE AND WELLTOLERATED IN ADULTS WITH ATOPIC DERMATITIS WITH MODERATE-TO-SEVERE HAND INVOLVEMENT WHO ARE CANDIDATES FOR SYSTEMIC THERAPY: WEEK 16 RESULTS FROM THE PHASE 3B ADHAND TRIAL, Benjamin Ehst, Richard Warren, Hong Chih-Ho, Juan F. Silvestre, Dong Hun Lee, Galina Balakirski, Andrei Metelista, Niels H. Bennike, Teodora Festini, Farzaneh Safavimanesh, and Linda F. Stein Gold
64656 52-Week Disease Control and Safety With As-Needed Application of Ruxolitinib Cream in Children Aged 2 to 11 Years With Moderate and/or More Extensive Atopic Dermatitis: Subgroup Analysis From the TRuE-AD3 Study, Lawrence F. Eichenfield, Eric L. Simpson, April W. Armstrong, Linda F. Stein Gold, Lara W. Lee, Kanwaljit K. Brar, Joel C. Joyce, Brett Angel, Daniel Sturm, Haobo Ren, and Andrea Zaenglein
64595 Embolia Cutis Medicamentosa: An Underrecognized Diagnosis Associated with Injectable Medication Use, Maria Espinosa, Saloni Shah, Karla Navarro, and Alison Boucher
62005 Characterizing suspected and confirmed drug-resistant dermatophytosis through the launch of the AAD/ILDS Drug Resistant Dermatophytes Registry, Esther Freeman, Morvarid Zehtab, Sidra Khan, Ditte Saunte, Avrom Caplan, Christine Li, Seemal Desai, and Henry W. Lim
Early acne improvements with fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel: What to expect in the first 4 weeks of treatment, Julie C. Harper, Leon H. Kircik, Michael Gold, Adelaide A. Hebert, Jeffrey L. Sugarman, Lawrence Green, Linda F. Stein Gold, Hilary Baldwin, James Q. Del Rosso, and Eric Guenin
0517 scRNA-seq identifies atopic dermatitis development marked by early neutrophils and T cell shifts in filaggrin-null mice with environmental sensitivity, Autumn Hicks, Mohammed H. M Barmal, A. Schmidt, Q. Zheng, Congcong Yin, Peter Dimitrion, Qing-Sheng Mi, Aimin Jiang, E. Grice, Indra Adrianto, and Cristina de Guzman Strong
Improvement in Atopic Dermatitis Signs and Symptoms With Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.15% or 0.05%: the 52-Week Phase 3 INTEGUMENT-OLE Trial in ≥2-year-olds, H. Chih-ho Hong, Eric Simpson, Lawrence F. Eichenfield, Alexandra Golant, Adelaide A. Hebert, Amy Paller, April Armstrong, Linda F. Stein Gold, Jonathan I. Silverberg, Patrick Burnett, Diane Hanna, Melissa S. Seal, and Brett Stephenson
β-catenin in dendritic cells negatively regulates CD8 T cell immune responses through the immune checkpoint molecule Tim-3, Aimin Jiang, Chunmei Fu, Jie Wang, Tianle Ma, Congcong Yin, Li Zhou, Bjoern E. Clausen, and Qing-Sheng Mi
0969 Exploring BMI-associated gene expression patterns in hidradenitis suppurativa lesions through transcriptional profiling, Sahil Kapur, Jeffrey Cruz, Randy Mi, Xzaviar K. Solone, Meyer Gershater, Iltefat Hamzavi, Indra Adrianto, and Qing-Sheng Mi
61571 Cryofibrinogenemia secondary to multiple myeloma presenting as digital necrosis, Mardeen S. Karim, Ben J. Friedman, and Sasank Konda
61909 Evidence-based hair care products and practices to use while scalp cooling, Lily Kaufman, Lucy Rose, Olivia Ueltschi, Samantha Rojas, Kateri Schoettinger, Madison Novice, Taylor Novice, Kimberly Salkey, Maria Hordinsky, and Brittany Dulmage
63465 A Comparison of the Risk of Major Cardiovascular Events, Venous Thromboembolism, Serious Infections, and Malignancies Among Patients With Vitiligo in the United States Using Real-World Data, Brett King, Viktoria Eleftheriadou, Claire C. Bristow, Danielle M. Conrad, Nada Elbuluk, Albert Wolkerstorfer, Harvey Lui, Emma Yue, Sarah Ofori, Thierry Passeron, and Iltefat Hamzavi
63755 Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: Efficacy and Safety Results from 4 Clinical Trials, Leon H. Kircik, Zoe D. Draelos, Edward Lain, Julie C. Harper, Hilary Baldwin, Linda F. Stein Gold, Michael Gold, and Eric Guenin
The influence of hormone therapy and BRCA mutation on development of breast carcinoma in young transgender patients, Christina Koehler, Mulin Xiong, Kiranpreet Kaur, Albert Young, Jasmine Jones, and Amy Kirby
Deucravacitinib in plaque psoriasis: laboratory parameters through 4 years of treatment in the Phase 3 POETYK PSO-1, PSO-2, and LTE trials, Neil J. Korman, Thierry Passeron, Yukari Okubo, Jerry Bagel, Richard B. Warren, Lynda Spelman, Kevin Winthrop, Kim Hoyt, Thomas Scharnitz, Subhashis Banerjee, Diamant Thaçi, Mona Shahriari, and Linda F. Stein Gold
Impact of risankizumab on disease symptoms in patients with non-pustular palmoplantar psoriasis: Post hoc analysis of the phase IIIb IMMprint study, Mark Lebwohl, Michael Bukhalo, Linda F. Stein Gold, Brad Glick, Mar Llamas-Velasco, Samuel Sanchez-Rivera, David Cotter, Anqi Pan, Cuiyong Yue, Manish Patel, Ramon Espaillat, Blair Kaplan, Lynda Spelman, and Robert Bissonnette
61479 Pigmentary disorders, prevalence, impact on quality of life, social stigmatization: results of the first large international survey in North America (I'SPOT study), Henry W. Lim, Andrew Alexis, Sergio Schalka, Brigitte Dréno, Jean Krutmann, Jorge O. Candiani, Caroline Le Floc'h, Delphine Kerob, Thierry Passeron, and Khaled Ezzedine
0419 Exposure risk of sunburns in the development of keratinocyte carcinoma: A meta analysis, Jalal Maghfour, J. Meisenheimer, M. Hook-Sobotka, and R. Dellavalle
63530 Pseudoporphyrias: A Systematic Review and Meta-analysis, Meghan Mansour, Madison Romanski, Nicholas Belair, Mohsen Mokhtari, and Joseph Fakhoury
Key Treatment Attributes and Preferences of Allergists and Dermatologists for Moderate-To-Severe Atopic Dermatitis: Results from a US-Based Real-World, Cross-Sectional Study, Vinay Mehta, Linda Stein-Gold, Alexandra Golant, Peter Lio, Raj Chovatiya, Zach Dawson, Evangeline Pierce, Louise A. DeLuca-Carter, James Haughton, James Piercy, Peter Anderson, and Bob Geng
Targeting mucosal associated invariant T (MAIT) cells via the gut microbiome as a novel immunotherapy for pancreatic cancer liver metastasis, Qing-Sheng Mi, Jugmohit Toor, Kalpana Subedi, Jie Wang, and Li Zhou
0203 HS progress: Baseline characteristics and disease impact, V. Nielsen, M. Lowes, A. Yates, A. Alavi, R. Flowers, Iltefat Hamzavi, J. Kirby, R. Micheletti, C. Sayed, and H. Naik
110: Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: Study design of phase 3 OCEANA clinical trials COAST1/2, SHORE, AQUA, and ESTUARY, Amy Paller, Linda F. Stein Gold, Stephan Weidinger, Delphine Staumont-Sallé, Saeko Nakajima, Eric Simpson, Marjolein de Bruin-Weller, Nacima Demil, Sonya Davey, Kassim Rahawi, and Charlotte Bernigaud
0756 Cannabidiol as a potential sunscreen additive: A survey of peer-reviewed literature, G. G. Papadeas, M. Szeto, M. Reed, Andrina Paul, T. M. Runion, J. Anderson, and R. Dellavalle
0643 TAK1 regulates langerhans cell homeostasis through MAPK and ER stress-activated autophagic machinery, Nirmal Parajuli, Qiyan Wang, Qian Yu, Qing-Sheng Mi, and Li Zhou
61478 Pigmentation disorders in North America Results of International Survey on Pigmentation-disorders Observational Tracking [I'SPOT] study, Thierry Passeron, Andrew Alexis, Brigitte Dréno, Sergio Schalka, Jorge O. Candiani, Caroline Le Floc'h, Delphine Kerob, Jean Krutmann, Henry W. Lim, and Khaled Ezzedine
61480 The interplay of pigmentation disorders and phototype in shaping perceived stigmatization: findings from the I'SPOT survey, Thierry Passeron, Andrew Alexis, Samir Salah, Akimichi Morita, Brigitte Dréno, Sergio Schalka, Delphine Kerob, Jean Krutmann, Henry W. Lim, and Khaled Ezzedine
The Interplay of Pigmentation Disorders and Phototype in Shaping Perceived Stigmatization: Findings from the I’spot Survey, Thierry Passeron, Andrew Alexis, Samir Salah, Akimichi Morita, Brigitte Dréno, Sergio Schalka, Delphine Kerob, Jean Krutmann, Henry W. Lim, and Khaled Ezzedine
62661 Dupilumab as a Therapeutic Approach for Keloids: A Review of Current Evidence, Akash Rau, Karan Pandher, David Gao, and Natalie Matthews
ERYTHRODERMIC PUSTULAR PSORIASIS TRIGGERED BY RED LIGHT/LASER THERAPY, Ingrid Rocha, Emily Falkowski, Meghan R. Mansour, Thomas Hagerman, Jalal Maghfour, Rachel Karmally, and Holly Kerr
63170 Analysis of oral, topical, and compounded minoxidil prices and insurance coverage, Lucy Rose, Samantha Rojas, Sonja Kobayashi, Olivia Ueltschi, Stephanie Adame, Kimberly Salkey, Maria Hordinsky, and Brittany Dulmage
PCR32 Bimekizumab Improves Work Productivity in Patients With Hidradenitis Suppurativa: 2-Year Results From BE HEARD EXT, Sylke Schneider-Burrus, Eleni Sotiriou, Iltefat Hamzavi, Tiffany Mayo, Peter Foley, Lynda Spelman, Toshifumi Nomura, Simon F. Thomsen, Jérémy Lambert, Michael F. Mørup, Nicola Tilt, and Martina L. Porter
60359 Utilizing Health Savings Accounts to Enhance Dermatological Care: Eligibility and Benefits, Sarah Shareef, Disha Bhargava, and Kurt Ashack
Lebrikizumab improves atopic dermatitis and quality of life in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab: Results from the ADapt trial, Jonathan I. Silverberg, Lindsay Ackerman, Jerry Bagel, Linda F. Stein Gold, Andrew Blauvelt, David Rosmarin, Raj Chovatiya, Matthew Zirwas, Gil Yosipovitch, Jill Waibel, Jenny E. Murase, Ben Lockshin, Jamie Weisman, Amber R. Atwater, Cynthia Harris, Jennifer Proper, Maria Silk, Evangeline Pierce, Maria L. Buziqui Piruzeli, Sonia Montmayeur, Christopher Schuster, Jinglin Zhong, Maria J. Rueda, Sreekumar Pillai, and Eric Simpson
64513 Continuous response with nemolizumab up to 56 weeks during a long-term extension study in patients with moderate-to-severe atopic dermatitis and partial or delayed skin response at Week 16 – Post-hoc analyses from the pooled ARCADIA 1&2 trials and long-te, Jonathan I. Silverberg, Linda F. Stein Gold, Diamant Thaci, Andrew Pink, Kim Papp, Franz J. Legat, Soo Yeon Cheong, Anna Ryzhkova, Liliana Ulianov, and Christophe Piketty
Efficacy and Safety of Ruxolitinib Cream Monotherapy in Patients Aged 2 Years and Older With Mild-to-Moderate Atopic Dermatitis: Results From 3 Large Randomized Phase 3 Studies, Eric Simpson, Lawrence Eichenfield, Kim Papp, Leon Kircik, Andrew Blauvelt, Linda F. Stein Gold, Andrea Zaenglein, Lara W. Lee, Christopher Bunick, Seth Forman, Kristen Holl, Howard Kallender, Daniel Sturm, Haobo Ren, and April Armstrong
